Mindfulness And Placebo for Pain (MAPP) Study
Active, not recruitingNot applicableNCT06720909
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study proposes a three-arm randomized-controlled trial (RCT) that evaluates the feasibility and acceptability of combining a mindfulness-based therapy (MBT) and open-label placebo (OLP) treatment for individuals with chronic pain. Individuals with chronic pain will be recruited to participate in an 8-week trial, with a subsequent 3-month post-treatment follow-up. Participants will be randomly assigned to one of the following three conditions: 1. Mindfulness-Based Stress Reduction (MBSR) 2. OLP treatment 3. combination of MBSR and OLP treatment
Study details
- Official title
- Feasibility of Combining Mindfulness Intervention and Open-Label Placebo Treatment for Chronic Pain
- Conditions
- Interventions
- Behavioral: Mindfulness-Based Stress Reduction (MBSR)
- Other: Open-Label Placebo (OLP)
- Other: MBSR+OLP
- Sponsor
- Arizona State University
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- Start date
- 2025-01-27
- Primary completion
- 2027-03-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. ≥18 years old; 2. ability to speak, write, and read in English; 3. physical pain present on at least half the days in the past 3 months; and 4. average past week pain severity rating ≥3 on a 0-10 Numerical Rating Scale. Exclusion Criteria: 1. acute pain due to recent injury or surgery; 2. self-reporting of chronic malignant pain (e.g., cancer, HIV); 3. self-reporting of Raynaud's disease (those who can be contraindicated for cold pressor testing); 4. severe psychopathology (e.g., a psychotic disorder) or significant cognitive deficits judged to interfere with study procedures; 5. currently pregnant or breastfeeding; 6. inability to discontinue use of vitamin B2 supplements or a multivitamin containing vitamin B2 throughout the study period (these interfere with riboflavin tracer-OLP treatment adherence-monitoring); 7. inability to commit to study period.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06720909